CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
F-18 16 alpha-fluoroestradiol +5 moreradiation
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00602043
NCT00602043Phase 2Completed
CompareCT.gov

A Phase 2 Study of [18F] Fluoroestradiol (FES) as a Marker of Hormone Sensitivity of Metastatic Breast Cancer

National Cancer Institute (NCI)·interventional·Posted Jan 28, 2008·Updated Feb 19, 2020

In Brief

A Phase 2 clinical trial evaluating F-18 16 alpha-fluoroestradiol, fludeoxyglucose F 18, and 3 other interventions for Estrogen Receptor-positive Breast Cancer and 4 related conditions. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This phase II trial is studying how well F-18 16 alpha-fluoroestradiol (FES) imaging works in predicting response to first-line hormone therapy in women with hormone receptor-positive metastatic breast cancer. Diagnostic procedures, such as FES imaging, may help predict how well patients will respond to hormone therapy and may help plan the best treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEstrogen Receptor-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 28, 2008
Enrollment StartSep 1, 2008
Primary CompletionAug 1, 2011
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 18.4 years ago

Interventions

F-18 16 alpha-fluoroestradiolradiation

Undergo \[\^18F\] FES PET

fludeoxyglucose F 18radiation

Undergo standard clinical FDG PET/CT

positron emission tomographyprocedure

Undergo \[\^18F\] FES PET

positron emission tomographyprocedure

Undergo standard clinical FDG PET/CT

computed tomographyprocedure

Undergo standard clinical FDG PET/CT

laboratory biomarker analysisother

Correlative studies